Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

By J. Bussel, G. Cheng, M. Saleh, B. Psaila, L. Kovaleva, B. Meddeb, J. Kłoczko, H. Hassani, B. Mayer, N. Stone and 3 more. New England Journal of Medicine, 2007

798 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/37db141229aee3ea6f9be37aec938003b17ad044

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Provan
2. J. Bussel
3. D. Cines
4. R. Stasi
5. F. Rodeghiero
6. A. Newland
7. T. Gernsheimer
8. V. Blanchette

Citations in the corpus

• Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. (2009, neutral): “It varies depending on the mechanism of action of the specific agent (Table 3).(4,6-10,40-52) The frequency of monitoring of platelet counts and the timing of response assessment should be prespecified and will depend on the expected kinetics of platelet increase after each treatment.”
• International consensus report on the investigation and management of primary immune thrombocytopenia. (2010, result): “Although reported in rodent studies with eltrombopag, there was no increase in cataracts observed in the ITP studies.(88;90;95) Liver function test abnormalities were seen in 13% of eltrombopag-treated patients.”